SpringWorks Therapeutics (NASDAQ:SWTX) Stock Quotes, Forecast and News Summary

Q: What sector and industry does SpringWorks Therapeutics (SWTX) operate in?

SpringWorks Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

SpringWorks Therapeutics Stock (NASDAQ: SWTX) stock price, news, charts, stock research, profile.

Open	$56.49
Close	-
Volume / Avg.	879.99K / 1.85M
Day Range	$55.52 - $57.19
52 Wk Range	28.21 - 60.00
Market Cap	$4.16B
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	71
Short Interest	23.43%
Days to Cover	11.51

Recent News

WeRide, CRISPR And GeneDx Are Among Top 10 Mid-Cap Gainers Last Week (Feb 10-Feb 14): Are The Others In Your Portfolio?

Top performing mid-cap stocks last week: WRD (+97.62%), GDS (+43.45%), SWTX (+42.58%), RXRX (+40.59%), SOC (+39.09%), WGS (+28.23%), VNET (+28.22%), NSP (+25.99%), CRSP (+25.21%), AXSM (+24.01%)

Lekha Gupta

SpringWorks Therapeutics Secures FDA Approval For Second Cancer Drug

SpringWorks' Gomekli wins FDA approval for NF1-related tumors, showing strong efficacy in trials. U.S. launch expected in two weeks, with EU review ongoing.

Vandana Singh

Germany's Merck In Talks To Buy Cancer Drug Maker SpringWorks Therapeutics

Merck KGaA is in advanced talks to acquire SpringWorks, whose portfolio could bolster Merck's oncology business amid patent expirations and competition.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Analyst Trends and Forecast

Aug 24

Sep 24

Nov 24

Jan

Feb

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.3

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Open	$56.49
Close	-
Volume / Avg.	879.99K / 1.85M
Day Range	$55.52 - $57.19
52 Wk Range	28.21 - 60.00
Market Cap	$4.16B
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	71
Short Interest	23.43%
Days to Cover	11.51

About SpringWorks Therapeutics Inc

Sector

Health Care

Industry

Biotechnology

SpringWorks Therapeutics Inc is a clinical stage biopharmaceutical company applying a precision medi...

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

How do I buy SpringWorks Therapeutics (SWTX) stock?

You can purchase shares of SpringWorks Therapeutics (NASDAQ:SWTX) through any online brokerage.

View our list of the best stock brokerages

Who are SpringWorks Therapeutics (SWTX) competitors?

Other companies in SpringWorks Therapeutics’s space includes: Immunovant (NASDAQ:IMVT), Legend Biotech (NASDAQ:LEGN), Ultragenyx Pharmaceutical (NASDAQ:RARE), Avidity Biosciences (NASDAQ:RNA) and Ascentage Pharma Group (NASDAQ:AAPG).

What is the forecast, or price target, for SpringWorks Therapeutics (SWTX) stock?

SpringWorks Therapeutics has a consensus price target of $65.25.

What is the current price for SpringWorks Therapeutics (SWTX)?

The stock price for SpringWorks Therapeutics (NASDAQ: SWTX) is $55.98 last updated February 19, 2025 at 8:01 AM EST.

Does SpringWorks Therapeutics (SWTX) pay a dividend?

There are no upcoming dividends for SpringWorks Therapeutics.

When is SpringWorks Therapeutics (NASDAQ:SWTX) reporting earnings?

SpringWorks Therapeutics’s Q1 earnings are confirmed for Thursday, May 1, 2025.

Is SpringWorks Therapeutics (SWTX) going to split?

There is no upcoming split for SpringWorks Therapeutics.

What sector and industry does SpringWorks Therapeutics (SWTX) operate in?

SpringWorks Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Comments

SpringWorks Therapeutics

SpringWorks Therapeutics (SWTX) Forecast